NASDAQ:XGN - Nasdaq - US30068X1037 - Common Stock - Currency: USD
Overall XGN gets a fundamental rating of 2 out of 10. We evaluated XGN against 561 industry peers in the Biotechnology industry. XGN may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, XGN is valued expensive at the moment.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -38.48% | ||
ROE | -242.18% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 59.3% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 2.87 | ||
Debt/FCF | N/A | ||
Altman-Z | -7.63 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.32 | ||
Quick Ratio | 2.32 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:XGN (5/23/2025, 2:42:47 PM)
6.74
+0.71 (+11.77%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 2.13 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 18.84 | ||
P/tB | 18.84 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -38.48% | ||
ROE | -242.18% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 59.3% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 2.87 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 31.77% | ||
Cap/Sales | 0.96% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 2.32 | ||
Quick Ratio | 2.32 | ||
Altman-Z | -7.63 |